-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2026-526102-33-00
2
2026-05-11
No medical condition
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2024-515438-33-00
5
2026-01-12
Alopecia areata
-
2025-521624-30-00
4
2026-01-08
Atopic dermatitis
-
2025-522113-35-00
4
2026-01-07
Atopic dermatitis
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-519531-41-00
5
2025-10-31
Overweight and obesity
-
2024-520155-24-00
4
2025-10-16
Metastatic castration resistant prostate cancer (mCRPC)
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-513572-17-00
5
2025-08-20
Generalized Anxiety Disorder (GAD)
-
2025-521098-14-00
5
2025-08-15
GZP1, GZP2: Obesity, Overweight
GZP2: Type 2 Diabetes